Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10396352 | 0.90 | MAPT (0.67) | MAPTPOLBMAPK1NPC1HTT | |
| SCHEMBL28594338 | 0.90 | MAPT (0.83) | MAPTPOLBMAPK1NPC1HTT | |
| SCHEMBL10948187 | 0.86 | KEAP1 (0.63) | MAPTPOLBMAPK1NPC1HTT | |
| SCHEMBL26738 | 0.84 | MAPT (1.00) | MAPTPOLBMAPK1NPC1HTT | |
| SCHEMBL29979531 | 0.84 | MAPT (1.00) | MAPTPOLBMAPK1NPC1HTT | |
| SCHEMBL4259849 | 0.83 | MAPT (1.00) | MAPTPOLBMAPK1NPC1HTT | |
| SCHEMBL3543844 | 0.83 | MAPT (0.73) | MAPTPOLBMAPK1NPC1HTT | |
| SCHEMBL28099842 | 0.83 | MAPT (0.52) | MAPTPOLBMAPK1NPC1HTT | |
| SCHEMBL3542735 | 0.83 | MAPT (0.67) | MAPTPOLBMAPK1NPC1HTT | |
| SCHEMBL17193968 | 0.81 | CYP1A2 (0.67) | MAPTPOLBHTTKDM4EPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809605-B1 | QUINOLINES AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7728142-B2 | 3-methanesulfonylquinolines as GABAB enhancers | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7576217-B2 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2009041904-A1 | QUINOLINE COMPOUNDS HAVING AN ACTIVITY AGAINST THE GABAB RECEPTOR | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009041904-A1 | QUINOLINE COMPOUNDS HAVING AN ACTIVITY AGAINST THE GABAB RECEPTOR | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
| US-20090088441-A1 | Quinoline Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088441-A1 | Quinoline Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088441-A1 | Quinoline Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| CN-101189208-A | 3-methanesulfonylquinolines as GABA-B enhancers | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | CN | disclosed |
| EP-1893560-A2 | 3-METHANESULFONYLQUINOLINES AS GABA-B ENHANCERS | F. Hoffmann-Roche AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| US-4169150-A | MUSCLE RELAXANTS, HYPNOSIS, ANTICONVULSANTS, SEDATIVES | TEIJIN LIMITED (JP) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MAPT 1003/4885POLB 3659/4885MAPK1 1/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPT 1000/4885POLB 3399/4885MAPK1 16/4885 |
| US-20090088441-A1 | Quinoline Compounds | GABRB1, HRH2, GABRA5 | MAPT 3267/4885POLB 3717/4885MAPK1 3486/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPT 978/4885POLB 3644/4885MAPK1 22/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPT 1000/4885POLB 3399/4885MAPK1 16/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAPT 1102/4885POLB 3168/4885MAPK1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.